Increase of Angiogenesis and Osteogenesis by Local Application of Simvastatin Depends on VEGF

Jie Tan,Hong Wang,Guohong Du,Huijie Leng,Chunli Song
DOI: https://doi.org/10.21203/rs.3.rs-69245/v1
2020-01-01
Abstract:Abstract Aims Simvastatin stimulates both BMP-2 and VEGF expression, but it is unknown which is more important for bone formation. This study was undertaken to determine whether these effects could be blocked by the anti-VEGF antibody bevacizumab. Methods 60 Sprague–Dawley male rats were randomly divided into five groups (n = 12 per group): normal control; simvastatin 0 mg or 0.5 mg; and bevacizumab with simvastatin 0 mg or 0.5 mg. Simvastatin groups were administered intraosseous injections of simvastatin delivered by thermosensitive poloxamer. Bevacizumab groups were given bevacizumab intraperitoneally or the same volume of saline. Serum samples were collected before the treatment and every two weeks thereafter. Four weeks after the treatment, four rats randomly selected from each group were subjected to Microfil® perfusion. The remaining eight rats was evaluated with dual energy X-ray absorptiometry (DXA) and micro-computed tomography (µCT). Four specimens (left tibias) were randomly selected from each group for undecalcified histology, the other four specimens selected for Western blot to analyse the changes of expression of BMP-2. Results local injection of simvastatin significantly increased bone formation. Microfil® perfusion showed that there were more vessels both in the bone marrow and around the bone after a single-dose simvastatin injection. Western blot analysis also confirmed that the expression levels of BMP2 were significantly higher in the simvastatin-treated groups compared with the control group. Compared with the simvastatin group, bevacizumab blunted the simvastatin-induced increase in bone mass and angiogenesis. Conclusion The anabolic effect of simvastatin on bone formation is through VEGF-related mechanisms.
What problem does this paper attempt to address?